+------------------------------------------------------------------------------+ |TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) | +------------------------------------------------------------------------------+
+----------------------------------------------+-------------------------------+ |1. Identity of the issuer or the underlying | | |issuer | Summit Therapeutics PLC | |of existing shares to which voting rights are | Sedol BN40HZ0 | |attached: (ii) | | +----------------------------------------------+-------------------------------+ |2 Reason for the notification (please tick the appropriate box or boxes): | +-------------------------------------------------------------------------+----+ |An acquisition or disposal of voting rights | | +-------------------------------------------------------------------------+----+ |An acquisition or disposal of qualifying financial instruments which may | | |result in the acquisition of shares already issued to which voting rights| | |are attached | | +-------------------------------------------------------------------------+----+ |An acquisition or disposal of instruments with similar economic effect to| | |qualifying financial instruments | | +-------------------------------------------------------------------------+----+ |An event changing the breakdown of voting rights | | +-------------------------------------------------------------------------+----+ |Other (please specify): Voluntary baseline disclosure upon implementation| X | | of amendments to the Transparency Directive | | +--------------------------------------+----------------------------------+----+ | |(1)Lansdowne Partners International | |3. Full name of person(s) subject to |Limited | |the | | |notification obligation: (iii) |(2)Lansdowne Partners Limited | | | | | |(3)Lansdowne Partners (UK) LLP | +--------------------------------------+---------------------------------------+ | |HSBC Client Holdings Nominee (UK) Ltd, | |4. Full name of shareholder(s) |HSBC Bank Plc Lansdowne Markets | | (if different from 3.):iv | | | |(Registered Shareholders) | +--------------------------------------+---------------------------------------+ |5. Date of the transaction and date on| | |which the threshold is crossed or |26/11/2015 | |reached: (v) | | +--------------------------------------+---------------------------------------+ |6. Date on which issuer notified: |30/11/2015 | +--------------------------------------+---------------------------------------+ |7. Threshold(s) that is/are crossed or|Voluntary baseline disclosure upon | |reached: (vi, vii) |implementation of amendments to the | | |Transparency Directive | +--------------------------------------+---------------------------------------+
+-------------------------------------------------------------------------------+ |8. Notified details: | +-------------------------------------------------------------------------------+ |A: Voting rights attached to shares (viii, ix) | +------------+----------------------+-------------------------------------------+ |Class/type |Situation previous |Resulting situation after the triggering | |of |to the triggering |transaction | |shares |transaction | | | +----------+-----------+---------+-----------------+---------------+ |if possible |Number |Number |Number |Number of voting |% of voting | |using |of |of |of shares|rights |rights (x) | |the ISIN |Shares |Voting +---------+------+----------+------+--------+ |CODE | |Rights |Direct |Direct|Indirect |Direct|Indirect| | | | | |(xi) |(xii) | | | +------------+----------+-----------+---------+------+----------+------+--------+ | Ordinary | | | | | | | | | Shares |11,077,170|11,077,170 | | |11,077,170| |18.07% | | | | | | | | | | |GB00BN40HZ01| | | | | | | | +------------+----------+-----------+---------+------+----------+------+--------+
+-------------------------------------------------------------------------------+ |B: Qualifying Financial Instruments | +-------------------------------------------------------------------------------+ |Resulting situation after the triggering transaction | +--------------+----------+--------------------+------------------+-------------+ |Type of |Expiration|Exercise/ |Number of voting |% of voting | |financial |date |Conversion Period |rights that may be|rights | |instrument |(xiii) |(xiv) |acquired if the | | | | | |instrument is | | | | | |exercised/ | | | | | |converted. | | +--------------+----------+--------------------+------------------+-------------+ | American | | | | | | Depositary | N/A | N/A | 4,650,000 | 7.59% | | Shares (ADS) | | | | | +--------------+----------+--------------------+------------------+-------------+
+-------------------------------------------------------------------------------+ |C: Financial Instruments with similar economic effect to Qualifying Financial | |Instruments (xv, xvi) | +-------------------------------------------------------------------------------+ |Resulting situation after the triggering transaction | +-------------+---------+----------+----------+------------------+--------------+ |Type of |Exercise |Expiration|Exercise/ |Number of voting |% of voting | |financial |price |date |Conversion|rights instrument |rights (xix, | |instrument | |(xvii) |period |refers to |xx) | | | | |(xviii) | | | +-------------+---------+----------+----------+------------------+-------+------+ | | | | | |Nominal|Delta | | | | | | +-------+------+ | | | | | | | | +-------------+---------+----------+----------+------------------+-------+------+
+-------------------------------------------------------------------------------+ |Total (A+B+C) | +------------------------------------+------------------------------------------+ |Number of voting rights |Percentage of voting rights | +------------------------------------+------------------------------------------+ |15,727,170 |25.66% | +------------------------------------+------------------------------------------+
+------------------------------------------------------------------------------+ |9. Chain of controlled undertakings through which the voting rights and/or the| |financial instruments are effectively held, if applicable: (xxi) | +------------------------------------------------------------------------------+ |Lansdowne Partners International Limited is the parent undertaking of | |Lansdowne Partners Limited which is the First Corporate Member of Lansdowne | |Partners (UK) LLP | +------------------------------------------------------------------------------+
+------------------------------------------------------------------------------+ |Proxy Voting: | +---------------------------------------------+--------------------------------+ |10. Name of the proxy holder: | | +---------------------------------------------+--------------------------------+ |11. Number of voting rights proxy holder will| | |cease | | |to hold: | | +---------------------------------------------+--------------------------------+ |12. Date on which proxy holder will cease to | | |hold | | |voting rights: | | +---------------------------------------------+--------------------------------+
+----------------------------+-------------------------------------------------+ | | | |13. Additional information: |Based on total voting rights of 61,290,740 | | | | | | | +----------------------------+-------------------------------------------------+ |14. Contact name: |Ruari Paton | +----------------------------+-------------------------------------------------+ |15. Contact telephone |+44 020 7290 5500 | |number: | | +----------------------------+-------------------------------------------------+
This announcement is distributed by GlobeNewswire on behalf of GlobeNewswire clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Summit Therapeutics plc via GlobeNewswire [HUG#1970344]
A0DKWDBN40HZ0R101
Copyright RTT News/dpa-AFX